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See Article, pages 672–680In Europe and the United States, hepatitis C virus (HCV)-related
end-stage liver disease is the main indicator of the need for liver
transplantation (LT). Recurrence of hepatitis C in the graft is uni-
versal after LT in HCV RNA-positive candidates, leading to lobular
or chronic active hepatitis in most patients and to cholestatic
hepatitis in a minority of them. Cirrhosis occurs in 20–30% of
transplant recipients within 5–10 years of transplantation [1]
and at least 10% of patients will require re-transplantation for
hepatitis C graft failure. Following transplantation, a signiﬁcant
increase in viral load is observed as the HCV follows a more
aggressive course in immunocompromised patients when com-
pared to competent patients. As a result, patient and graft sur-
vival are lower in HCV-positive recipients than in HCV-negative
recipients [2]. Antiviral therapy based on pegylated interferon
(Peg-IFN) in combination with ribavirin (RBV) is primarily given
when there is histological evidence of recurrent HCV disease.
However, as in the non-transplant setting, its efﬁcacy is lower
in HCV genotype 1 infected patients. The reported sustained viro-
logical response (SVR) rate with Peg-IFN and RBV in genotype 1
patients ranges from 12% to 40% (mean 28.7%) and is lower than
in non-transplant patients [3]. Factors potentially responsible for
the reduced virological response to Peg-IFN and RBV therapy in
the setting of LT are: prior non-response to (Peg) IFN and RBV
before transplantation, high prevalence of genotype 1, immuno-
suppression, intolerance, and side effects of IFN or RBV. Tolerabil-
ity is a major issue, with 70–80% of patients requiring dose
reduction and 10–40% requiring drug discontinuation [3]. Most
studies show improvements in biochemical and necroinﬂamma-
tory activity in virological responders. Less consistent improve-
ments in ﬁbrosis scores have been reported, possibly due to the
stage of ﬁbrosis at the initiation of therapy, with more advanced
stages being less reversible [4,5]. A survival beneﬁt was also
reported in virological responders [6,7]. Predictive factors associ-
ated with SVR are: initial viral kinetics and more speciﬁcally viralJournal of Hepatology 20
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E-mail address: didier.samuel@pbr.aphp.fr (D. Samuel).response assessed at 4 and 12 weeks of therapy, non genotype1,
adherence to therapy, baseline viremia, and baseline ﬁbrosis
stage (Table 1) [3].
In this issue of the journal, Fukuhara et al. reported for the
ﬁrst time in transplant patients, a role of HCV genotype 1b muta-
tions in sensitivity to Peg-IFN and RBV therapy [8]. The predictive
potential of the combined analysis of viral mutations that
included amino acid(s) (aa) 70 and 91 in the Core region, the
interferon sensitivity-determining region (ISDR, aa 2209–2248),
and the interferon/ribavirin resistance determining region
(IRRDR, aa 2334–2379) in the NS5A region, was retrospectively
evaluated. Fifty genotype 1 patients were treated with increasing
doses of Peg-IFN alpha-2b and RBV. Nineteen patients were non-
responders to standard IFN therapy before transplantation.
Twenty-two (44%), 8 (16%), and 20 (40%) patients demonstrated
SVR, relapse, and non-response, respectively. The pre-treatment
viral load and low haemoglobin level were signiﬁcant risks fac-
tors for the failure to achieve SVR. Native liver tissues and serum
at liver transplantation were available for genetic analysis from
16 and 22 patients, respectively. The sequences of aa 70 and 91
in the Core region, ISDR and IRRDR between liver tissues and
serum were the same in the 12 patients in which both liver tis-
sues and serum were available. Post-transplant liver tissues and
serum were analyzed in 10 and 6 patients, respectively. The
sequences of the Core and NS5A regions in the pre- and post-
transplant samples were identical, except for aa 70 in the Core
of only one patient. The patients were divided into two groups
based on the mutation of aa 70 and 91 in the Core region (DW
and non-DW), the number of ISDR mutations (ISDRP2 and ISDR
<2) and the number of IRRDR mutations (IRRDR P6 and IRRDR
<6). The rate of SVR was signiﬁcantly lower in the non-double
wild at aa 70 and 91, the ISDR <2 and IRRDR <6 groups than in
the double wild (30% vs. 65%, p = 0.015), the ISDR P2 (35% vs.
69%, p = 0.035), and IRRDR P6 (25% vs. 78%, p <0.001) groups. A
predictive scoring system based on the number of positive factors
including the double wild in the Core region, ISDRP2 and IRRDR
P6 in the NS5A region could be established before transplanta-
tion and allowed the stratiﬁcation of the sensitivity of antiviral
therapy after LT. The rate of SVR in this prediction score was10 vol. 52 j 630–632
Table 1
Predictive factors associated with sustained virologic response to interferon–
ribavirin therapy post-transplantation.
Host factors
Virologic response at week 4 Conﬁrmed
Virologic response at week 12 Conﬁrmed




Low baseline ﬁbrosis stage Probable (Refs. [4,5])
Low baseline activity score Not proven
Viral factors
Genotype 2 or 3 Conﬁrmed
Low baseline HCV viral load Conﬁrmed
HCV genotype 1 mutations One study (Ref. [8])
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18%, 38%, 86%, and 100% for the presence of 0, 1, 2, or 3 positive
factors, respectively (p <0.001). The results reported in this study
are important since no other pre-transplant predictor, for the
achievement of SVR after antiviral therapy post-transplant in
genotype 1 patients, has been reported. A limitation of this study
is the absence of a multivariate analysis of the predictive factors
of SVR in order to evaluate the importance of viral factors as com-
pared to early viral kinetics and other pre- and on-treatment pre-
dictors of response.
In the non-transplant setting, some studies from western
countries and Japan reported that in patients with chronic HCV
genotype 1 infection, there is a strong correlation between
response to IFN and mutations in the NS5A protein, particularly
in the ISDR and IRRDR regions [9–12] and at aa 70 and 91 of
the Core region [13,14]. In the study of Shirakawa et al., the mul-
tivariate logistic regression analysis for factors associated with
SVR showed that mutant ISDR was the strongest predictor
(OR = 86.0, 95% CI 6.4–1162.3) as compared to early viral kinetics
(OR = 12.0, 95% CI 2.4–60) or total dose of Peg-IFN (OR = 23.1, 95%
CI 2.7–194.9) [12].
Few studies have analyzed the effect of virological factors
(except genotype) on the outcome of HCV recurrence post-LT.
Feliu et al. assessed the early virological response to antiviral
therapy in a cohort of 11 patients treated immediately before
and after LT and compared HCV sequences from hyper-variable
region 1 and NS5A region before both treatments [15]. Eight
patients showed identical early viral kinetics to both courses of
therapy and interestingly the type of response changed in 3
patients: 2 non-responders obtained early virological response
and an early virological responder became a non-responder.
The differences between the sequences of the NS5A region were
very few, suggesting that the changes in sensitivity to therapy
after LT are not exclusively dependent on variations in HCV
strains and might be related to host factors. However, sequence
analysis of the NS5A region showed that ﬁxation of mutations
in this region occurred preferentially in individuals who became
sensitive to IFN after LT. Another study showed that the NS3 and
the NS5B regions evolved independently after LT [16]. The
genetic evolution of the NS3 domain was not related to the sever-
ity of the recurrence. However, the diversiﬁcation in the NS5B
region was greater in patients with mild recurrences than in
those with severe recurrences, suggesting that immune pressure
was stronger in the former group. In a previous study we found a
strong positive correlation between genetic variability in the Core
sequences of 53 genotype 1 patients and differences in 5-year
ﬁbrosis scores and in viral load [17]. Following LT, there are major
changes in viral and host variables that might inﬂuence the
response to therapy: (a) the variation in quasi-species composi-
tion after LT; (b) the genetic background of the liver graft is sin-
gular and the activation of IFN-dependent antiviral pathways
may be different in each individual; (c) the immune pressure
on HCV is modiﬁed by immunosuppression. Taking these factors
into consideration, pre-transplant prediction of response to anti-
viral therapy after LT seems very difﬁcult. As in the non-trans-
plant setting, the decision to treat should take into account all
parameters: age, general status, genotype, severity of the hepati-
tis, rapidity of ﬁbrosis progression, risk of graft loss, and expected
tolerance to the treatment. The presence of HCV mutations may
represent a new tool that may help in the decision to undertake
antiviral therapy post-transplantation but in no way it does it
represent a factor limiting the indication of transplantation. ThisJournal of Hepatology 201new technique is not fully evaluated and should be assessed in
larger studies. A multifactorial approach could improve the
management of HCV recurrence post-transplantation: better
graft selection and particularly younger donor age, accurate
follow-up of HCV re-infection by yearly liver histology and/or
non-invasive markers of ﬁbrosis, better management of immuno-
suppression, avoidance of rejection episodes, treatment of co-fac-
tors such as insulin resistance, and improved modalities of
antiviral therapy such as use of hematopoietic growth factors
[18–21]. However, a favourable long-term outcome for recipients
of HCV-infected graft after LT is more likely to be brought about
by the development of new, highly effective antiviral therapies
that can prevent or treat recurrent hepatitis C.
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